Floatz logo

CM-101 CCL24 BLOCKING MONOCLONAL ANTIBODY

Primary Sclerosing Cholangitis

ChemomAb Ltd.monoclonal_antibodyPhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the Primary Sclerosing Cholangitis cohort.

Asset / SponsorPhaseRating
Vancomycin
Tampere University Hospital
Phase 4BB
URSODEOXYCHOLIC ACID
Assistance Publique - Hôpitaux de Paris
Phase 3BB
Elafibranor
Ipsen
Phase 3B
Aldafermin
NGM Biopharmaceuticals, Inc
Phase 2/3B
htd1801
HighTide Biopharma Pty Ltd
Phase 2B

View all 50 →

Same molecule, other indications

CM-101 CCL24 BLOCKING MONOCLONAL ANTIBODY is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative · Phase 2
64 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
CC
Indicative · Phase 1
46 / 100
View asset →
systemic sclerosisDormant
CC
Indicative · Phase 1
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →